Review of antifungal therapy, part II: Treatment rationale, including specific patient populations

Journal of Dermatological Treatment

Volumn 19, Issue 3, 2008, Pages 168-175

  Baran, Robert ^a   Hay, Rod J ^b   Garduno, Javier I ^c  

^a NAIL DISEASE CENTRE   (France)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Antifungal; Combination therapy; Onychomycosis; Special populations; Treatment

Indexed keywords

AMOROLFINE; AMPHOTERICIN B; ANTIFUNGAL AGENT; BIFONAZOLE; CICLOPIROX; FLUCONAZOLE; ITRACONAZOLE; STEROID; TERBINAFINE;

ALOPECIA AREATA; CANDIDA; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONGENITAL DISORDER; DEBRIDEMENT; DERMATOPHYTE; DIAGNOSTIC ERROR; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG PENETRATION; DRUG POTENTIATION; DRUG RESEARCH; ECZEMA; HUMAN; IMMUNOCOMPROMISED PATIENT; LEG ULCER; MONOTHERAPY; NAIL DYSTROPHY; ONYCHOLYSIS; ONYCHOMYCOSIS; PARONYCHIA; PATHOGENESIS; PATIENT COMPLIANCE; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; REVIEW; RISK ASSESSMENT; TINEA; TINEA CAPITIS; TINEA PEDIS; TREATMENT FAILURE; TRICHOPHYTON RUBRUM;

ADULT; AGED; ANTIFUNGAL AGENTS; ARTHRODERMATACEAE; CHILD; DEBRIDEMENT; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; MITOSPORIC FUNGI; NAILS; ONYCHOMYCOSIS; OPPORTUNISTIC INFECTIONS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS;

EID: 45849129837     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630701657187     Document Type: Review

References (83)

1. De Gentile L, Bouchara JP, Le Clec'h C, et al. Prevalence of Candida ciferrii in elderly patients with trophic disorders of the legs. Mycopathologia. 1995;131:99-102.
2. Contet-Audonneau N, Schmutz JL, Basile AM, et al. A new agent of onychomycosis in elderly: Onychocola canadensis. Eur J Dermatol. 1997;7:115-17.
3. Seebacher C, Ulbricht H, Wörz K. Topical therapy of onychomycoses in geriatric patients. TW Dermatol. 1993;23:434-8.
4. Gupta AK, Skinner AR. Onychomycosis in children: A brief overview with treatment strategies. Pediatr Dermatol. 2004;21:74-9.
5. Suarez S. New antifungal therapy for children. Adv Dermatol. 1997;12:195-209.
6. Gupta AK, Chang P, del Rosso JQ, et al. Onychomycosis in children: Prevalence and management. Pediatr Dermatol. 1998;15:464-71.
7. Williams TG, Hall M. Lack of interaction of oral terbinafine with oral contraceptives and healthy babies in a postmarketing surveillance study. Fifth Annual International Summit on Cutaneous Antifungal Therapy, Singapore; 1998. Abstract 67.
8. Gupta AK, Taborda P, Taborda V, et al. Epidemiology and prevalence of onychomycosis in HIV-positive individuals. Int J Dermatol. 2000;39:746-53.
9. Cribier B, Leiva Mena M, Rey D, et al. Nail changes in patients infected with immunodeficiency virus. A prospective controlled study. Arch Dermatol. 1998;134:1216-20.
10. Conant MA. The AIDS epidemic. J Am Acad Dermatol. 1994;31:S47-S50.
11. Ravnborg L, Baastrup N, Svejgaard E. Onychomycosis in HIV-infected patients. Acta Derm Venereol. 1998;78:151-2.
12. Goldman GD, Bolognia JL. HIV-related skin disease: Managing fungal infections. J Respir Dis. 1997;18:14-20.
13. Herranz P, Garcia J, De Lucas R, et al. Toenail onychomycosis in patients with acquired immune deficiency syndrome: Treatment with terbinafine. Br J Dermatol. 1997;139:577-80.
14. Dompmartin D, Dompmartin A, Deluol AM, et al. Onychomycosis and AIDS. Int J Dermatol. 1990;29:337.
15. Arrese JE, Piérard-Franchimont C, Piérard GE. Fatal hyalohyphomycosis following Fusarium onychomycosis in an immunocompromised patient. Am J Dermatopathol. 1996;18:196-8.
16. Martino P, Gastaldi R, Raccah R, et al. Clinical patterns of Fusarium infections in immunocompromised patients. J Infect. 1994;28 Suppl 1:7-15.
17. Evans EGV. Causative pathogens in onychomycosis and the possibility of treatment resistance: A review. J Am Acad Dermatol. 1998;38:S32-S36.
18. Chugh KS, Sharma SC, Singh V, et al. Spectrum of dermatological lesions in renal allograft recipient in a tropical environment. Dermatology. 1994;188:108-12.
19. Gülec AT, Demirbilek M, Seckin D, et al. Superficial fungal infection in 102 renal transplant recipients. A case control. J Am Acad Dermatol. 2003;49:187-92.
20. Virgili A, Zampino MR, La Malfa V. Prevalence of superficial dermatomycoses in 73 renal transplant recipients. Dermatology. 1999;199:31-4.
21. Weglowska J, Szepietowski J, Walow B, et al. Onychomycosis in renal transplant recipient. Part II. Mycological aspects. Mikok Lek. 2003;10:307-11.
22. Gupta AK, Scher RK, de Doncker P. Current management of onychomycosis. Dermatol Clin. 1997;15:121-35.
23. Denning DW, Evans EG, Kibbler CC, et al. Fungal nail disease: A guide to good practice. BMJ. 1995;311:1271-81.
24. Baran R, De Doncker P. Lateral edge involvement indicates poor prognosis for treating onychomycosis with the new systemic antifungals. Acta Derm Venereol. 1996;73:82-3.
25. Sommer S, Sheean-Dare RA, Goodfield MJD, Evans EGV. Prediction of outcome in the treatment of onychomycosis. Clin Exp Dermatol. 2003;28:425-8.
26. Hay RJ. Chronic dermatophyte infections. In: Verbov J, editor. Superficial fungal infections. Lancaster, UK: MTP Press; 1986. p. 23-4.
27. Roberts DT, Evans EGV. Subungual dermatophytoma complicating dermatophyte onychomycosis. Br J Dermatol. 1998;138:189-90.
28. Frederiksson T. The pros and cons of an oral treatment of dermatomycosis. Dermatologica. 1984;169 Suppl 1:67-8.
29. Epstein E. How often does oral treatment of toenail onychomycosis produce a disease-free nail? An analysis of published data. Arch Dermatol. 1998;134:1551-4.
30. Nolting S. Onychomycosis. New approaches in therapy. Proceedings of the 19th World Congress of Dermatology, Sydney, 1997:12.
31. Ghannoum MA. Future of antimycotic therapy. Dermatol Ther. 1997;3:104-11.
32. Polak-Wyss A. Mechanism of action of antifungals and combination therapy. J Eur Acad Dermatol Venereol. 1995;4 Suppl 1:511-16.
33. Olafsson J, Sigurgeirsson B, Baran R. Combination therapy for onychomycosis. Br J Dermatol. 2003;149 Suppl 64:15-18.
34. Gupta AK, Fleckman P, Baran R. Ciclopirox nail lacquer topical solution 8% in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2000;43:S70-S80.
35. Gupta AK and the Onychomycosis Combination Therapy Study Group, Ciclopirox topical solution, 8% combined with oral terbinafine to treat onychomycosis: A randomized, evaluator-blinded study. J Drugs Dermatol. 2005;4:481-5.
36. Kim HC, Jung KB, Shin DH, et al. Comparison of compliance and cure rate of systemic antifungal therapy versus combination therapy with systemic and topical agent in toenail onychomycosis. Korean J Med Mycol. 2002;7:35-41.
37. Baran R, Feuilhade M, Datry A, et al. A randomized trial of amorolfine 5% solution nail lacquer combined with oral terbinafine compared with terbinafine alone in the treatment of dermatophytic toenail onychomycosis affecting the nail region. Br J Dermatol. 2000;142:1177.
38. Baran E, Bochenski J, Duczkowski M, et al. Combination therapy for onychomycosis with amorolfine nail lacquer and oral antifungal agents. Mikol Lek. 2003;10:79-83.
39. Yoon YH, An JY, Ro BI. Experience of combination treatment of toenail onychomycosis with oral itraconazole and topical 5% amorolfine nail lacquer. Korean JMed Mycol. 2004;9:159-65.
40. Lecha M, Alsina M, Torres M, et al. Amorolfine and itraconazole combination for severe toenail onychomycosis: Results of an open randomised trial in Spain. Br J Dermatol. 2001;145 Suppl 60:21-6.
41. Rigopoulos D, Katoulis A, Ioannides D, et al. A randomised trial of amorolfine 5% solution nail lacquer in association with itraconazole pulse therapy compared with itraconazole alone in the treatment of Candida fingernail onychomycosis. Br J Dermatol. 2003;149:151.
42. Sergeev Y, Sergeev A. Pulsed combination therapy: The new option for onychomycosis. Mycoses. 2001;44 Suppl 1:68.
43. Harman S, Ashbee HR, Evans EG. Testing of antifungal combinations against yeasts and dermatophytes. J Dermatol Treat. 2004;15:104-7.
44. Gupta AK, Konnikov N, Lynde CW. Sequential pulse therapy with itraconazole and terbinafine to treat onychomycosis of the fingernails. J Dermatol Treat. 2000;11:151-4.
45. Gupta AK, Lyde CW, Konnikov N. Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. J Am Acad Dermatol. 2001;44:485-91.
46. Gupta AK, Del Rosso JQ. An evaluation of intermittent therapy used to treat onychomycosis and other dermatomycoses with the oral antifungal agents. Int J Dermatol. 2000;39:401-11.
47. Tausch I, Bräutigam M, Weiding G. Evaluation of 6 weeks treatment of terbinafine in tinea unguium in a double-blind trial comparing 6 and 12 weeks therapy. Br J Dermatol. 1997;136:737-42.
48. Watson A, Marley J, Ellis D, et al. Terbinafine in onychomycosis of the toenail: A novel treatment protocol. J Am Acad Dermatol. 1995;33:775-9.
49. Haneke E, Ring J, Abeck D. Efficacy of itraconazole pulse treatment in onychomycosis. HGZ Hautkr. 1997;72:737-40.
50. De Cuyper C. Therapeutic approach of recalcitrant toenail onychomycosis. Fifth International Summit on Cutaneous Antifungal Therapy, Singapore; 1998. Abstract 26, .
51. Sigurgeirsson B, Paul C, Curran D, Evans EGV. Prognostic factors of mycological cure following treatment of onychomycosis with oral antifungal agents. Br J Dermatol. 2002;147:1241-3.
52. Zaias N, Rebell G. The successful treatment of Trichophyton rubrum nail bed (distal subungual) onychomycosis with intermittent pulse-dosed terbinafine. Arch Dermatol. 2004;140:691-5.
53. Di Chiacchio N, Kadunc BV, De Almeida ART, et al. Nail abrasion. J Cosmet Dermatol. 2003;2:150-2.
54. Goodfield MJD, Evans EGV. Combined treatment with surgery and short duration oral antifungal therapy in patients with limited dermatophyte toenail infection. J Dermatol Treat. 2000;11:259-62.
55. Daniel CR, Daniel MP, Daniel CM, et al. Chronic paronychia and onycholysis: A thirteen-year experience. Cutis. 1996;58:397-401.
56. Elewski BE. Bacterial infection in a patient with onychomycosis. J Am Acad Dermatol. 1997;37:493-4.
57. Tosti A, Piraccini BM. Paronychia. In: Amin S, Maibach H, editors. Contact urticaria syndrome. Boca Raton, FL: CRS Press; 1997. p. 276-8.
58. Baran R, Hay R, Perrin Ch. Superficial white onychomycosis revisited. J Eur Acad Dermatol Venereol. 2004;18:569-71.
59. Ellis DH, Marley JE, Watson AB. Significance of nondermatophyte moulds and yeasts in onychomycosis. Dermatology. 1997;194 Suppl 1:40-2.
60. Arenas R, Dominguez-Cherit J, Fernandez L. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol. 1995;34:138-43.
61. Baran R. Nail fungal infections and treatment. Hand Clin. 2002;18:625-8.
62. Gupta AK, Baran R, Summerbell R. Onychomycosis: Strategies to improve efficacy and reduce recurrence. J Eur Acad Dermatol Venereol. 2002;16:579-86.
63. Shuster S, Baran R. Recurrence of fungal nail disease and the dissociation of relapse from re-infection. Acta Derm Venereol. 2001;81:154-5.
64. Ogawa H, Summerbell RC, Clemons KV, et al. Dermatophytes and host defence in cutaneous mycoses. Med Mycol. 1998;36:166-73.
65. Woodfolk JA, Platts-Mills TA. The immune response to dermatophytes. Res Immunol. 1998;149:436-45.
66. Wagner DK, Sohnle PG. Cutaneous defenses against dermatophytes and yeasts. Clin Microbiol Rev. 1995;8:317-35.
67. Jones HE. Cell-mediated immunity in the immunopathogenesis of dermatophytosis. Acta Derm Venereol. 1986; Suppl 121:73-83.
68. Jones HE. Factors involved in producing a sustained experimental dermatophyte infection (Trichophyton mentagrophytes). Cutis. 2001;67:18-19.
69. Svejgaard E. Humoral antibody responses in the immunopathogenesis of dermatophytosis. Acta Derm Venereol. 1986;121 Suppl:73-83.
70. Kaaman T. Cell-mediated reactivity in dermatophytosis: Differences in skin responses to purified Trichophyton in tinea pedis and tinea cruris. Acta Derm Venereol. 1981;61:119-23.
71. Dahl MV, Grando SA. Chronic dermatophytosis: What is special about Trichophyton rubrum? Adv Dermatol. 1994;9:97-109.
72. Dahl MV. Dermatophytosis and the immune response. J Am Acad Dermatol. 1994;31:S34-S41.
73. Zaias N, Rebell G. Chronic dermatophytosis caused by Trichophyton rubrum. J Am Acad Dermatol. 1996;35:S17-S20.
74. Artis WM, Jones HE. The effect of human lymphokine on the growth of Trichophyton mentagrophytes. J Invest Dermatol. 1982;74:131-4.
75. Poulain D, Tronchin G, Vernes A, Delabre M, Biguet J. Experimental study of resistance to infection by Trichophyton mentagrophytes: Demonstration of memory skin cells. J Invest Dermatol. 1982;74:205-9.
76. Kaaman T. Dermatophyte antigens and cell-mediated immunity in dermatophytosis. Curr Top Med Mycol. 1985;1:117-34.
77. Hernandez AD, Reece RE, Zucker AH. Trichophyton mentagrophytes spores differ from mycelia in the ability to induce pustules and activate complement. J Invest Dermatol. 1986;87:683-7.
78. Ninomiya J, Ide M, Ito Y, Takiuchi I. Experimental penetration of Trichophyton mentagrophytes into the human stratum corneum. Mycopathologia. 1998;141:153-7.
79. Jones HE. Immune response and host resistance of humans to dermatophyte infection. J Am Acad Dermatol. 1993;28:S12-S18.
80. Galitz J, Schein JR. Symptom improvement in patients with onychomycosis receiving oral antifungal therapy. South Med J. 2002;95:1359-60.
81. Maleszka R, Adamski Z, Dworacki G. Evaluation of lymphocytic subpopulations and natural killers in peripheral blood of patients treated for dermatophyte onychomycosis. Mycoses. 2001;44:487-92.
82. Maleszka R. Enzymatic activity of dermatophytes in various forms of onychomycosis. Mikol Lek. 1999;6:77-83.
83. De Doncker P, Degreef H, André J, Pierard G. Why are some with onychomycosis still not responding to the newer antifungal agents? Orlando, AAD; 1998. Poster 187.